Human epidermal growth factor receptor 2 (HER2)-negative subset is the most heterogeneous group of metastatic breast cancers (MBCs) as it includes both hormone receptor (HR)-positive and HR-negative breast cancer (or TNBC), which have different therapies and treatment challenges. Though endocrine therapy (ET) remains the treatment backbone in HR-positive HER2-negative cases, about 40% of the patients show intrinsic or acquired resistance to ET due to multiple mechanisms. Combining different therapies such as ET and other targeted therapies with or without chemotherapy fails to give continued benefit, unlike cyclin-dependent kinase (CDK) 4/6 inhibitors that have shown a great benefit. TNBC has conventionally been treated ineffectively with systemic chemotherapy. Recently, poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged for HER2-negative breast cancer (BC) patients, including TNBC. Olaparib and talazoparib have recently been approved in germline BRCA-mutated (gBRCAm) HER2-negative MBC. Additionally, ongoing trials of PARPi in combination with various therapies are expected to provide more and better treatment options for gBRCAm HER2-negative breast cancer.

中文翻译：

---

人表皮生长因子受体 2 阴性转移性乳腺癌的治疗：聚二磷酸腺苷（ADP-核糖）聚合酶抑制剂的作用。

人表皮生长因子受体 2 (HER2) 阴性亚群是最异质的转移性乳腺癌 (MBC) 组，因为它包括激素受体 (HR) 阳性和 HR 阴性乳腺癌 (或 TNBC)，它们有不同的治疗方法和治疗挑战。尽管内分泌治疗 (ET) 仍然是 HR 阳性 HER2 阴性病例的治疗支柱，但由于多种机制，约 40% 的患者对 ET 表现出内在或获得性耐药。与已显示出巨大益处的细胞周期蛋白依赖性激酶 (CDK) 4/6 抑制剂不同，将不同的疗法（例如 ET 和其他靶向疗法与或不与化学疗法相结合）不能带来持续的益处。TNBC 传统上用全身化疗治疗无效。最近，聚 (ADP-核糖) 聚合酶抑制剂 (PARPi) 已用于 HER2 阴性乳腺癌 (BC) 患者，包括 TNBC。奥拉帕尼和他拉唑帕尼最近已被批准用于生殖系 BRCA 突变 (gBRCAm) HER2 阴性 MBC。此外，正在进行的 PARPi 试验与各种疗法相结合，有望为 gBRCAm HER2 阴性乳腺癌提供更多更好的治疗选择。